Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | PHASE2 | ACTIVE NOT_RECRUITING | 540 | — | — | Jun 28, 2023 | Apr 1, 2027 | Sep 22, 2025 | 50 | United States |
The Clinical Dementia Rating (CDR) is a clinical scale that describes 5 levels of impairment in performance on each of 6 categories of function including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The ratings of degree of impairment obtained on each of the 6 categories of function are synthesized into 1 global rating of dementia as absent, questionable, mild, moderate, or severe (global CDR scores of 0, 0.5, 1, 2, or 3, respectively). The score is based on interviews with the participant and study partner, using a structured interview. A sum of boxes score (CDR-SB) provides an additional measure of change where each category has a maximum possible score of 3 points and the total score is a sum of the category scores giving a total possible score of 0 to 18 with higher scores indicating more impairment.
| Arm | Type | Description |
|---|---|---|
| CT1812 100 mg | ACTIVE_COMPARATOR | CT1812 at a dose of 100 n=180 group |
| CT1812 200 mg | ACTIVE_COMPARATOR | CT1812 at a dose of 300mg, n=180 group |
| Placebo | PLACEBO_COMPARATOR | Placebo, n=180 group |
| Name | Type | Description |
|---|---|---|
| CT1812 | DRUG | Study Drug |
| Placebo | DRUG | Non-active study drug |
Inclusion Criteria: 1. Ages 50-85 years. 2. Diagnosis of either MCI due to AD or mild AD dementia. 3. MMSE 20-30 (inclusive). 4. Amyloid PET scan of the brain or CSF biomarkers consistent with AD. 5. Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's ...